BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16903165)

  • 1. Successful control of dyslipidemia in patients with metabolic syndrome: focus on lifestyle changes.
    Stone NJ
    Clin Cornerstone; 2006; 8 Suppl 1():S15-20. PubMed ID: 16903165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic basis of atherogenic dyslipidemia.
    Vinik AI
    Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal.
    McKenney JM
    Pharmacotherapy; 2003 Sep; 23(9 Pt 2):26S-33S. PubMed ID: 14524636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyslipidemia in the metabolic syndrome in children.
    Gidding SS
    J Cardiometab Syndr; 2006; 1(4):282-5. PubMed ID: 17679808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome: therapeutic considerations.
    Grundy SM
    Handb Exp Pharmacol; 2005; (170):107-33. PubMed ID: 16596797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
    Falko JM; Moser RJ; Meis SB; Caulin-Glaser T
    Curr Diabetes Rev; 2005 May; 1(2):127-35. PubMed ID: 18220588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of metabolic syndrome.
    Wagh A; Stone NJ
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
    Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
    Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New guidelines for managing hypercholesterolemia.
    McKenney JM
    J Am Pharm Assoc (Wash); 2001; 41(4):596-607. PubMed ID: 11486986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of dyslipidemia in the metabolic syndrome.
    Tan KC
    Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):99-108. PubMed ID: 17584044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines.
    Brewer HB
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III19-24. PubMed ID: 12708635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of the metabolic syndrome: the impact of lifestyle modification.
    Pritchett AM; Foreyt JP; Mann DL
    Curr Atheroscler Rep; 2005 Mar; 7(2):95-102. PubMed ID: 15727723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
    Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
    Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of atherogenic dyslipidemia in the development of metabolic syndrome].
    Real JT; Romero P; Martínez Hervas S; Pedro T; Carmena R; Ascaso JF
    Med Clin (Barc); 2006 Sep; 127(9):321-4. PubMed ID: 16987450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.